Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study

Main Article Content

Wayne Gulliver
Gordon Sussman
Jacques Hebert
Charles W Lynde
Kim A Papp
William H Yang
Olivier Chambenoit
Antonio Viera
Frederica DeTakaosy
Lenka Rihakova

Keywords

urticaria, omalizumab, chronic urticaria, biologic therapy

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Novartis.

 

Copyright 2018 SKIN